Lower risk for bleeding without increase in ischemic events seen for patients with acute coronary syndrome.
As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback